Sonidegib (Erismodegib, NVP-LDE225)

Catalog No.S2151

Sonidegib (Erismodegib, NVP-LDE225) Chemical Structure

Molecular Weight(MW): 485.5

Sonidegib (Erismodegib, NVP-LDE225) is a Smoothened (Smo) antagonist, inhibiting Hedgehog (Hh) signaling with IC50 of 1.3 nM (mouse) and 2.5 nM (human) in cell-free assays, respectively. Phase 3.

Size Price Stock Quantity  
In DMSO USD 210 In stock
USD 150 In stock
USD 270 In stock
USD 470 In stock
USD 700 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • RU-SKI 43 blocks Shh signaling. (a) RU-SKI 43 blocks Gli activation. NIH 3T3 cells were cotransfected with vectors encoding 8× Gli-binding site (GliBS)-Firefly luciferase (unless indicated otherwise), Renilla luciferase reporter (pRL-TK) and Shh. Confluent cells were treated with DMSO, 10 μM LDE225, 10 μM RU-SKI 43 or 10 μM C-2. The firefly luciferase (FL)/Renilla luciferase (RL) ratio in cell lysates was calculated and normalized to that measured in DMSO-treated samples; error bars represent mean ± s.d. (n = 2–3). 

    Nat Chem Biol 2013 9, 247-9. Sonidegib (Erismodegib, NVP-LDE225) purchased from Selleck.

    Western blot analysis on total cell lysates from renal cancer cell lines treated with NVP-LDE225 at different concentrations. Densitometric measurements were normalised to b-actin and reported under western blot images.

    Br J Cancer 2014 111(6), 1168-79. Sonidegib (Erismodegib, NVP-LDE225) purchased from Selleck.

  • NVP-LDE225, everolimus, sunitinib, and their combination interfere with actin and with intracellular organisation of focal adhesion points. Cytoskeleton organisation of 786-O SuR treated with NVP-LDE225 ( 2.5 uM ), everolimus (1 uM ), sunitinib (1 uM ), and their combination for 24 h was analysed by confocal microscopy. Actin-based structures were revealed by rhodaminated phalloidin staining (red fluorescence). Localisation of focal adhesion points was obtained by immunofluorescent staining of p-paxillin (green fluorescence). Merged row images show overlapping of p-paxillin and actin signals. Moreover, all captures were shown in transmitted light. Scale bars, 10 um.

    Br J Cancer 2014 111(6), 1168-79. Sonidegib (Erismodegib, NVP-LDE225) purchased from Selleck.

Purity & Quality Control

Choose Selective Hedgehog/Smoothened Inhibitors

Biological Activity

Description Sonidegib (Erismodegib, NVP-LDE225) is a Smoothened (Smo) antagonist, inhibiting Hedgehog (Hh) signaling with IC50 of 1.3 nM (mouse) and 2.5 nM (human) in cell-free assays, respectively. Phase 3.
Smo (mouse) [1]
(Cell-free assay)
Smo (human) [1]
(Cell-free assay)
1.3 nM 2.5 nM
In vitro

Sonidegib (Erismodegib, NVP-LDE225) inhibits TM3 luciferized cell line with 0.6 nM and 8 nM, at the presence of 1 nM and 25 nM Hh agonist Ag1.5, respectively. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A2780ip2 M{PWXmN6fG:6aXPpeJkh[XO|YYm= MYH+NVAh|ryP MVzJR|UxRTF{IN88US=> MYeyNlU2OzN3NR?=
A2780cp20 MmTqR5l1d3irY3n0fUBie3OjeR?= NH7iU4p,OTBizszN MV7JR|UxRTdwNTFOwG0> MUCyNlU2OzN3NR?=
SKOV3ip1 NXK2eYUxS3m2b4jpZ4l1gSCjc4PhfS=> MYf+NVAh|ryP NXTyfYJmUUN3ME2yOEDPxE1? MoHuNlI2PTN|NUW=
HeyA8 M1HGU2N6fG:6aXPpeJkh[XO|YYm= NIH2[2V,OTBizszN M{PhT2lEPTB;MUig{txO NX\Gd4dwOjJ3NUOzOVU>
HeyA8MDR M3\ycmN6fG:6aXPpeJkh[XO|YYm= M{nGfJ4yOCEQvF2= NHPueFZKSzVyPUig{txO M{TBZVIzPTV|M{W1
OS5 M{TabWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NH3YeHp,PSEQvF2= MYTy[YR2[2W|IITo[UBxem:uaX\ldoF1cW:w NH24TFUzOzJ2M{W5OS=>
OS18 M4\6U2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MXP+OUDPxE1? NGH0R5Nz\WS3Y3XzJJRp\SCycn;sbYZmemG2aX;u MYOyN|I1OzV7NR?=
Glioblastoma initiating cells MUHDfZRwgGmlaYT5JIF{e2G7 MkjLglExKM7:TR?= Ml:2TY5pcWKrdIOgR4VtdCCYaXHibYxqfHl? M3Xlb|I{PDh{Nkex
Glioblastoma initiating cells NUjnO5U3TnWwY4Tpc44h[XO|YYm= MWf+NVAh|ryP Mn7kbY5pcWKrdIOgcoV2em:|cHjldoUh\m:{bXH0bY9v MljnNlM1QDJ4N{G=
Glioblastoma initiating cells NWTO[ppES3m2b4jpZ4l1gSCjc4PhfS=> M{HZVZ4yOCEQvF2= NGe1R3BqdmS3Y3XzJIFxd3C2b4Ppdy=> NWXGOWZIOjN2OEK2O|E>
Glioblastoma initiating cells Moe5SpVv[3Srb36gZZN{[Xl? MorEglExKM7:TR?= M1jOSIRwf26{ZXf1cIF1\XNidHjlJHNJUCC|aXfuZYxqdmdicHH0bJdigQ>? NVvONoFJOjN2OEK2O|E>
Glioblastoma initiating cells M3TOZWZ2dmO2aX;uJIF{e2G7 M17wVp4yOCEQvF2= NHLid5ZKdmirYnn0d{B1cGViRYjwdoV{e2mxbjDv[kBI\W6nczDJcpZwdH[nZDDpckBO[WmwdHHpcolv\yCSbIXybZBwfGWwY4m= NFOwcoszOzR6Mk[3NS=>
Glioblastoma initiating cells MmjhSpVv[3Srb36gZZN{[Xl? M37HN54yOCEQvF2= NGCzUItKdmirYnn0d{BOd3SrbHn0fUwhUW64YYPpc44tKGGwZDDNbYdz[XSrb36= NWXORllpOjN2OEK2O|E>
LOX IMVI NH7CUINHfW6ldHnvckBie3OjeR?= M4nTclExKM7:TR?= MnH3SG1UVw>? MYrpcohq[mm2czDI[YRo\WixZz3HUGkheGG2aIfhfS=> M2HP[VI{QTN3OUK1
UACC 257 MoKxSpVv[3Srb36gZZN{[Xl? MWGxNEDPxE1? Mke3SG1UVw>? MXXpcohq[mm2czDI[YRo\WixZz3HUGkheGG2aIfhfS=> M2X5VlI{QTN3OUK1
UACC 257 M3nsTmZ2dmO2aX;uJIF{e2G7 MVqxNEDPxE1? MonjSG1UVw>? NIr0VohqdmS3Y3XzJGcyKGOnbHygZ5lkdGViYYLy[ZN1 NVrHTZBwOjN7M{W5NlU>
LOX IMVI Mn7oR5l1d3irY3n0fUBie3OjeR?= NXXMUZhMOTBizszN M1W2XmROW09? NXHOPG5T\GWlcnXhd4V{KHS3bX;yJINmdGxidnnhZoltcXS7 MUOyN|k{PTl{NR?=
UACC 257 NEnLWW1EgXSxeHnjbZR6KGG|c3H5 M33QcVExKM7:TR?= MmG5SG1UVw>? M1zrUYRm[3KnYYPld{B1fW2xcjDj[YxtKH[rYXLpcIl1gQ>? MXmyN|k{PTl{NR?=
LOX IMVI M3LiXWFxd3C2b4Ppd{Bie3OjeR?= M1;JTlExKM7:TR?= MkSySG1UVw>? M4S1OYlv\HWlZYOgZZBweHSxc3nz MnTwNlM6OzV7MkW=
ACHN MUHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NFH1dlB,PSEQvF2= NHLwV2VFVVOR M3z6cGlEPTB;Mj2z5qCK|ryP Mor3NlUxQTN2OUG=
769-P NVrPNZNDT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NUDG[GV3hjVizszN MmTQSG1UVw>? NVTlOXprUUN3ME2yMVPjiIoQvF2= M3\3W|I2ODl|NEmx
786-O SuR MXLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MXz+OUDPxE1? NIHS[plFVVOR M3no[GlEPTB;Mj2z5qCK|ryP MYqyOVA6OzR7MR?=
SP53 NEO3SGJHfW6ldHnvckBie3OjeR?= M1zvN|MxKM7:TR?= MU\EUXNQ NVq1eIE{cW6qaXLpeJMh[2WubDDh[Ihme2mxbjDhcoQhdWmpcnH0bY9v NHnxXWkzPjh6NU[wPC=>
SP53 NF7ZV2NHfW6ldHnvckBie3OjeR?= NUj5W5FTOzBizszN M1nhWGROW09? MkXTbY5pcWKrdIOgeIhmKF[OQUStcYVlcWG2ZXSgSmFMKHOrZ37hcIlv\yCyYYToe4F6 NH7ZdnEzPjh6NU[wPC=>
HS5 NXjXXVE4TnWwY4Tpc44h[XO|YYm= M{TvXFMxKM7:TR?= M3;nWWROW09? NGixVFdqdmirYnn0d{Bk\WyuIHHkbIV{cW:wIHHu[EBucWe{YYTpc44> M3fOdVI3QDh3NkC4
HS27a MXnGeY5kfGmxbjDhd5NigQ>? NUCzXI1uOzBizszN NHfUc2tFVVOR MV;pcohq[mm2czDj[YxtKGGmaHXzbY9vKGGwZDDtbYdz[XSrb36= MVSyOlg5PTZyOB?=
SP53 Mnf5R5l1d3irY3n0fUBie3OjeR?= Mli1N|Ah|ryP MknCSG1UVw>? MoHDbY5lfWOnczDheZRweGijZ4m= MUWyOlg5PTZyOB?=
Jeko NG\4TnZEgXSxeHnjbZR6KGG|c3H5 NVG3fWlbOzBizszN M{flVmROW09? NGKyTVFqdmS3Y3XzJIF2fG:yaHHnfS=> Mn3vNlY5QDV4MEi=

... Click to View More Cell Line Experimental Data

In vivo Sonidegib (Erismodegib, NVP-LDE225) is highly bound to mouse, rat, and human plasma proteins (>99%) and moderately bound to dog and monkey plasma proteins (77 and 85%, respectively). LDE225 has high permeability (90.8% in man) in the PAMPA assay. LDE225 shows good oral bioavailability ranging from 69 to 102% in preclinical species when dosed in solution. LDE225 is a weak base with a measured pKa of 4.20 and exhibits relatively poor aqueous solubility. LDE225 demonstrates dose-related antitumor activity. At a dose of 5 mg/kg/day qd, LDE225 significantly inhibits tumor growth, corresponding to a T/C value of 33%. When dosed at 10 and 20 mg/kg/day qd, LDE225 gives rise to 51 and 83% regression, respectively. Gli1 mRNA inhibition correlates with tumor and plasma exposure of LDE225. LDE225 successfully penetrates the blood−brain barrier in tumor-bearing animals and results in tumor growth inhibition after 4 days of treatment. [1] LDE225 significantly reduces the tumor volume by 95.7% in Rip1-Tag2 mice. LDE225 prolongs survival in Rip1Tag2 mice. LDE225 decreases expression of stromal markers in the LDE225-treated mice. [2]


Cell Research:


+ Expand
  • Cell lines: TM3Hh12 cells
  • Concentrations: ~10 μM
  • Incubation Time: 30 minutes
  • Method:

    LDE225 is prepared for assay by serial dilution in DMSO and then added to empty assay plates. TM3Hh12 cells (TM3 cells containing Hh-responsive reporter gene construct pTA-8xGli-Luc) are cultured in F12 Ham's/DMEM (1:1) containing 5% horse serum, 2.5% fetal bovine serum (FBS), and 15 mM HEPES, pH 7.3. Cells are harvested by trypsin treatment, resuspended in F12 Ham's/DMEM (1:1) containing 5% horse serum and 15 mM HEPES, pH 7.3, added to assay plates, and incubated with LDE225 for approximately 30 min at 37 °C in 5% CO2. Then 1 nM or 25 nM Ag1.5 is added to assay plates and incubated at 37 °C in the presence of 5% CO2. After 48 hours, either Bright-Glo or MTS reagent is added to the assay plates and luminescence or absorbance at 492 nm is determined. IC50 values, defined as the inflection point of the logistic curve, are determined by nonlinear regression of the Gli-driven luciferase luminescence or absorbance signal from MTS assay vs log10 (concentration) of LDE225 using the R statistical software pack

    (Only for Reference)
Animal Research:


+ Expand
  • Animal Models: Orthotopic Ptch+/-p53-/- medulloblastoma allograft model in athymic nude mice
  • Formulation: 0.5% sodium carboxymethyl cellulose
  • Dosages: 40 mg/kg/day
  • Administration: Administered via p.o. or b.i.d
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 97 mg/mL (199.79 mM)
Ethanol 97 mg/mL warmed (199.79 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+corn oil
For best results, use promptly after mixing.

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 485.5


CAS No. 956697-53-3
Storage powder
in solvent

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01787552 Completed Primary Myelofibrosis|Thrombocythemia Essential|Thrombocytosis|Myeloproliferative Disorders|Bone Marrow Diseases|Hematologic Diseases|Blood Coagulation Disorders|Blood Platelet Disorders|Hemorrhagic Disorders Novartis Pharmaceuticals|Novartis May 8 2013 Phase 1|Phase 2
NCT01708174 Completed Medulloblastoma Novartis Pharmaceuticals|Novartis May 6 2013 Phase 2
NCT02254551 Terminated Multiple Myeloma SCRI Development Innovations LLC|Novartis January 2015 Phase 2
NCT02195973 Completed Recurrent Ovarian Cancer University of Alabama at Birmingham|Novartis Pharmaceuticals September 2014 Phase 1
NCT02182622 Unknown status Prostate Cancer Martin Gutierrez|Novartis|Hackensack Meridian Health July 2014 Phase 1
NCT02151864 Active not recruiting Hepatocellular Carcinoma|Cirrhosis Jason K. Sicklick M.D.|Novartis Pharmaceuticals|University of California San Diego July 2014 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

Related Hedgehog/Smoothened Products

Tags: buy Sonidegib (Erismodegib, NVP-LDE225) | Sonidegib (Erismodegib, NVP-LDE225) supplier | purchase Sonidegib (Erismodegib, NVP-LDE225) | Sonidegib (Erismodegib, NVP-LDE225) cost | Sonidegib (Erismodegib, NVP-LDE225) manufacturer | order Sonidegib (Erismodegib, NVP-LDE225) | Sonidegib (Erismodegib, NVP-LDE225) distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID